Triple-negative breast cancer subtypes identified using microRNA

February 7, 2013, Ohio State University Medical Center

A new, large-scale study of triple-negative breast cancer shows that small molecules called microRNA can be used to define four subtypes of this aggressive malignancy.

The findings, by researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) working with collaborators in Italy, could lead to new , prognostic markers and perhaps new targeted treatments for this aggressive and often-fatal form of .

The study is published in the journal .

"The treatment of women with triple-negative breast cancer is challenging because this can be very different genetically from one patient to another," says co-senior investigator Dr. Charles Shapiro, director of Breast and professor of at the OSUCCC – James.

"We believe these microRNA signatures define novel sub-sets of triple-negative breast cancer and offer new insights into the biology of the disease and better ways to treat these patients," Shapiro says.

The microRNAs that compose the signatures are involved in regulating cell growth, proliferation and survival, and in cell movement and migration.

"These findings strongly suggest that microRNAs play an important role in triple-negative breast cancer and might be used to better identify the most effective treatment for a patient's tumor," says co-senior investigator and researcher Dr. Kay Huebner, professor of , immunology and at Ohio State.

"Several of the deregulated microRNAs we found in the cancer samples are involved in chemo-resistance or radio-resistance. MicroRNA profiles can help us to improve and personalize therapies for individual patients," she says.

Triple-negative breast cancer accounts for about 15 percent of all breast cancers. It is characterized by that lack estrogen, and HER2 receptors. For this reason, these tumors do not respond to hormone therapies or HER2-targeted treatments.

MicroRNAs help regulate the kind and amount of proteins that cells make. They do this by binding with messenger RNA (mRNA), molecular copies of genes that are translated into proteins. When microRNA is bound to an mRNA, the messenger molecule cannot be translated into a protein. Instead, it is either temporarily stored or destroyed.

This study investigated associations between microRNA expression levels, mRNA expression levels and overall survival and distant-disease-free survival in women with triple-negative breast cancer.

Shapiro, Huebner and their colleagues evaluated 59 normal, 165 tumor and 54 metastatic matched tissue samples, obtained through The Stefanie Spielman Fund for Breast Cancer Research at the OSUCCC – James.

The researchers ran a complete microRNA profile and a cancer-focused panel of genes for each sample. They then generated microRNA signatures represented by certain prognostic microRNAs that, when deregulated, indicate odds of survival.

"This was a large cohort of triple-negative breast cancer cases and a major analysis effort that we believe makes this work extremely valuable," Huebner says.

To stratify the cancers, the researchers determined microRNA and mRNA expression profiles in tumor, adjacent-normal tissue and lymph-node metastatic tissue from 173 women with the triple-negative breast cancer.

"We identified microRNAs and mRNAs that uniquely represent primary and metastatic tumors, and that are specifically deregulated in that stage of the disease, says co-author Dr. Pierluigi Gasparini, a postdoctoral researcher in Huebner's laboratory.

The results define microRNA expression signatures that characterize and contribute to the differences between primary and metastatic tumors.

"We now want to learn which of these deregulated microRNAs might represent early biomarkers for cancer or metastasis detection," Gasparini says.

The study's key technical findings include:

  • The microRNA signatures correlated with prognosis and were correlated with changes in mRNA expression;
  • Two microRNA signatures were predictive of overall survival and distant disease-free survival, respectively, in patients 50 years of age or younger;
  • mRNA expression profiling resulted in clustering of triple-negative breast cancer into four molecular subclasses with different expression signatures.
"We believe these findings will be a reference point not only for our lab but also for many other research teams that might not have access to large patient populations, and hope that they will accelerate even more research on triple-negative breast cancer," Huebner says.

Explore further: Researchers discover a DNA marker may indicate differences in breast cancer

More information: www.plosone.org/article/info:d … journal.pone.0055910

Related Stories

Researchers discover a DNA marker may indicate differences in breast cancer

June 2, 2012
Researchers and doctors at the North Shore-LIJ Health System and the Feinstein Institute for Medical Research have discovered a potential explanation for why breast cancer is not experienced the same way with African American ...

Breaking the backbone of triple-negative breast cancers

March 19, 2012
Putting the brakes on an abundant growth-promoting protein causes breast tumors to regress, according to a study published on March 19th in the Journal of Experimental Medicine.

How early breast tumors become deadly: A small group of molecules might hold the answer

February 7, 2012
Researchers have discovered a restricted pattern of molecules that differentiate early-stage breast tumors from invasive, life-threatening cancer. They also found a similar molecular signature that correlated with the aggressiveness ...

New hope for taming triple-negative breast cancer

October 2, 2012
Disease-free survival is short-lived for women with triple-negative breast cancer—a form of the disease that doesn't respond to hormone drugs and becomes resistant to chemotherapy. Thankfully, a promising line of study ...

Scientists reveal aggressive breast cancer's metastatic path

January 14, 2013
Scientists at Weill Cornell Medical College have discovered the molecular switch that allows aggressive triple negative breast cancer cells to grow the amoeba-like protrusions they need to crawl away from a primary tumor ...

Recommended for you

Student develops microfluidics device to help scientists identify early genetic markers of cancer

October 16, 2018
As anyone who has played "Where's Waldo" knows, searching for a single item in a landscape filled with a mélange of characters and objects can be a challenge. Chrissy O'Keefe, a Ph.D. student in the Department of Biomedical ...

Technique to 'listen' to a patient's brain during tumour surgery

October 16, 2018
Surgeons could soon eavesdrop on a patient's brain activity during surgery to remove their brain tumour, helping improve the accuracy of the operation and reduce the risk of impairing brain function.

Researchers elucidate roles of TP63 and SOX2 in squamous cell cancer progression

October 16, 2018
Squamous cell carcinomas (SCCs) are aggressive malignancies arising from the squamous epithelium of various organs, such as the esophagus, head and neck, lungs, and skin. Previous studies have demonstrated that two master ...

Function of neutrophils during tumor progression unraveled

October 15, 2018
Researchers at The Wistar Institute have characterized the function of neutrophils, a type of white blood cells, during early stages of tumor progression, showing that they migrate from the bone marrow to distant sites and ...

Delving where few others have gone, leukemia researchers open new path

October 15, 2018
A Wilmot Cancer Institute study uncovers how a single gene could be at fault in acute myeloid leukemia (AML), one of the deadliest cancers. The breakthrough gives researchers renewed hope that a gene-targeted therapy could ...

3-D mammography detected 34% more breast cancers in screening

October 15, 2018
In traditional mammography screening, all breast tissue is captured in a single image. Breast tomosynthesis, on the other hand, is three-dimensional and works according to the same principle as what is known as tomography. ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.